Copyright © 2013 John Wiley & Sons. ”
“There is a limited evidence base as to the benefits of continuous glucose monitoring (CGM) in clinical practice,

but it is clear that in order to realise improvements in glycaemic control when using CGM there is a requirement for both health care professionals and patients to have the ability to interpret the data obtained from CGM. This article describes a personal approach to analysing selleck chemicals CGM data using a structured approach and reporting tool, with examples to demonstrate how this system is implemented in practice. By viewing the daily overlay, then breaking the CGM traces into overnight, fasting/pre-meal and post-meal phases, and finally looking at the impact of other factors such as exercise, alcohol and work patterns, the user can be educated to make changes to NVP-LDE225 cell line both their insulin regimen and lifestyle to optimise glycaemic control. Those offered CGM as a real-time adjunct to their intensive insulin regimen need to have such a structured approach to get

positive re-inforcement and thus use CGM sufficiently frequently to gain real benefit from it. Copyright © 2012 John Wiley & Sons. ”
“Our aim was to study the impact of adding twice-daily exenatide in obese patients with type 2 diabetes and poor glycaemic control who were taking insulin therapy, either alone or in combination with oral hypoglycaemic agents (OHAs), in routine clinical pentoxifylline practice. Outcomes evaluated

were glycaemic control, body weight, insulin dose, tolerability, safety and incidence of hypoglycaemia. In an open-label prospective study, twice-daily exenatide was added to existing therapy in individuals with type 2 diabetes, suboptimal glycaemic control (HbA1c >7% [53mmol/mol]) and obesity (body mass index [BMI] <30kg/m2), who were receiving insulin therapy alone or in combination with OHA(s). Thirty-one patients (18 male) were mean (SD) age 55.7(8.6)years, weight 114.6(22.0)kg, BMI 39.1(5.6)kg/m2, waist circumference 128(13)cm and fasting capillary glucose 11.1(3.4)mmol/L. Median (IQR) known diabetes duration was 10.0(8.0, 17.9)years, HbA1c 9.5(8.8, 10.7)% and daily insulin dose 120(74, 230)units/day. Twenty patients were also taking metformin. One-month data were available for 29 patients, three-month data for 23 patients, six-month data for 28 patients and 12-month data for 21 patients. There was a mean (SD) reduction in weight from 1.1(2.6)kg (p=0.043) at one month to 4.8(7.3)kg (p=0.007) at 12 months, with a maximal reduction at six months (5.3[5.9]kg, p<0.001). Total daily insulin dose was reduced significantly by 31.8(56.5)units (p=0.010) at one month and 49.5(85.3)units (p=0.015) at 12 months. At three months there was a significant reduction in HbA1c (1.2[1.